Folate Is Not Folic Acid: Methylfolate, Folinic Acid, and Why the 400 mcg DFE on Your Multivitamin Label Is Probably the Wrong Form for the People Who Need It Most

Pick up three multivitamins off the same shelf. The first lists "folic acid, 400 mcg DFE" in the supplement-facts box. The second lists "folate, 400 mcg DFE (as L-methylfolate)" in the same line. The third lists "folate complex, 800 mcg DFE" with no form disclosed. Reach for a fourth bottle marketed as a "prenatal" — it lists "folic acid 800 mcg DFE." None of the four labels gives the buyer enough information to know whether the form in the bottle is the right form for the person taking it. Folate is not folic acid. Methylfolate is not folate. Folinic acid is not methylfolate. The four forms have different absorption, different conversion requirements, different dose-response curves, and different relevance depending on whether the buyer carries one of the common MTHFR polymorphisms. The label convention that compresses all of this into one DFE number on one line lets the buyer who does not understand the form-and-conversion math end up on the wrong protocol for the wrong reason.

This post is the form-and-dose-response math behind the four common folate forms in retail supplements: synthetic folic acid, natural food folate (5-methyltetrahydrofolate, food-source), supplemental L-methylfolate (the 5-MTHF active form), and folinic acid (5-formyl-THF, the calcium folinate form used in clinical settings). The folate-versus-folic-acid distinction, the MTHFR polymorphism question (overstated for the general population, real for the subset where the form choice matters), the DFE conversion that the FDA requires on labels, the dose-response curves the trial literature actually supports for the most-studied endpoints, the 1 mg masking issue most labels do not warn about, and the label patterns that separate a real folate product from a folic-acid product wearing a marketing label.

What folate, folic acid, methylfolate, and folinic acid actually are

Natural folate is the family of related water-soluble B-vitamin compounds found in food — primarily 5-methyltetrahydrofolate (5-MTHF), with smaller fractions of other reduced folates. The biologically active form circulating in plasma is 5-MTHF. Food folates are absorbed in the small intestine through specific transporters, deglutamated to monoglutamates, and delivered to circulation primarily as 5-MTHF.

Folic acid is the synthetic oxidized form (pteroylglutamic acid) used in supplements and in fortified food. Folic acid does not exist in significant amounts in nature. The body has to reduce it through two enzymatic steps — dihydrofolate reductase (DHFR) converts folic acid first to dihydrofolate then to tetrahydrofolate, and then methylenetetrahydrofolate reductase (MTHFR) converts the tetrahydrofolate derivatives to the active 5-MTHF. The two-step conversion is rate-limited at low DHFR activity (which is the standard human state in liver — DHFR activity in humans is much lower than in rodents) and at low MTHFR activity (which is the case for the common 677C→T and 1298A→C polymorphisms).

L-methylfolate (5-MTHF, the supplemental form) is the same molecule as the active circulating folate. It is the form the body uses directly without further conversion. Supplemental 5-MTHF is sold under several trade names (Metafolin, Quatrefolic, Magnafolate) and as generic L-methylfolate; the chemistries are equivalent in the active L-isomer (D-isomers are inactive and some early supplemental products contained the racemic mix). The conversion-bottleneck issue does not exist because the molecule is already in the active form.

Folinic acid (5-formyl-THF, calcium folinate / leucovorin) is another reduced folate that enters the folate cycle one step removed from active 5-MTHF. It is used clinically as the rescue agent after methotrexate and as a folate-cycle support in specific medical contexts. Folinic acid bypasses the DHFR step but still requires MTHFR-dependent conversion to active 5-MTHF, so it is not a complete bypass for MTHFR-variant individuals — but it is a more flexible folate-cycle substrate than folic acid.

The four forms are not interchangeable. Folic acid requires both DHFR and MTHFR to become active. Food folate enters the body as 5-MTHF already. Supplemental L-methylfolate is 5-MTHF and bypasses both bottlenecks. Folinic acid bypasses DHFR but not MTHFR. The label that says "folate 400 mcg DFE" without form disclosure has not told the buyer which of these four molecules they are buying.

The DFE convention that masks the form question on the label

The FDA requires folate to be expressed on supplement-facts labels in Dietary Folate Equivalents (DFE) to account for the difference in absorption between food folate, folic acid taken with food, and folic acid taken on an empty stomach.

The conversion is:

• 1 mcg of food folate = 1 mcg DFE
• 1 mcg of folic acid taken on an empty stomach = 2 mcg DFE (higher absorption)
• 1 mcg of folic acid taken with food = 1.7 mcg DFE
• 1 mcg of supplemental L-methylfolate = 1 mcg DFE (treated as food folate)

That means a label that says "folate, 400 mcg DFE (as folic acid)" actually contains about 240 mcg of folic acid (400 ÷ 1.7) — the DFE is an inflated number relative to the actual milligram dose of folic acid. A label that says "folate, 400 mcg DFE (as L-methylfolate)" contains 400 mcg of L-methylfolate. The two products report the same DFE but the folic acid product contains less milligrams of folate equivalent and requires the DHFR + MTHFR conversion the L-methylfolate product does not. The buyer who reads the label as if 400 mcg DFE were a simple "dose" is missing the form-and-conversion math the label collapses. Labels that disclose both numbers ("folate 680 mcg DFE (as folic acid 400 mcg)") let the buyer see the conversion; labels that disclose only the DFE leave it implicit.

The MTHFR polymorphism question

The MTHFR gene encodes the enzyme that converts the inactive folate forms to active 5-MTHF. Two common polymorphisms reduce enzyme activity at the population scale:

• 677C→T (rs1801133, the "thermolabile" variant). Roughly 10-15% of European-ancestry populations are homozygous (TT) and 40-50% are heterozygous (CT). Homozygotes have approximately 30% of wild-type MTHFR activity. Plasma folate runs lower at baseline, plasma homocysteine runs higher, and the conversion of folic acid to active 5-MTHF is slowed.
• 1298A→C (rs1801131). Less common as homozygous; the enzymatic impact is smaller than 677TT. Compound heterozygotes (677CT + 1298AC) have intermediate impact.

The clinical relevance of MTHFR polymorphisms outside specific contexts (recurrent pregnancy loss, methotrexate dosing, hyperhomocysteinemia workup, certain pediatric inborn-error contexts) is more limited than the consumer-genetics-influencer discourse suggests. For most adults with MTHFR variants, achieving adequate plasma 5-MTHF through normal dietary folate intake plus a standard supplemental dose is straightforward and the population-level case for "every MTHFR carrier needs L-methylfolate" overstates the evidence.

The case where the form choice actually matters is the buyer who is either pregnancy-trying or pregnant, or who has documented elevated homocysteine, or who is on medications that interfere with folate metabolism (methotrexate, sulfasalazine, certain antiepileptics, metformin chronically), or who is an older adult at B12-masking risk. For those populations, the L-methylfolate or food-folate form bypasses the MTHFR-conversion bottleneck and is preferable to folic acid. For the buyer with no MTHFR polymorphism, no medication interaction, no homocysteine elevation, and no pregnancy-related context, folic acid at the standard supplemental dose works.

The label-marketing posture that "methylfolate is required for everyone because MTHFR variants are common" overstates the population-level case. The form choice is genuinely useful for the subset for whom it matters; it is not load-bearing for the general adult.

The dose-response math

The trial-supported and DRI-supported doses for the most-relevant endpoints:

Adult RDA: 400 mcg DFE per day. From food, fortified food, or supplement. Covers the maintenance dose for adults without specific deficiency or pregnancy-related need.

Pregnancy / pregnancy-trying: 600 mcg DFE per day, with at least 400-600 mcg from a synthetic source (supplement or fortified food) for the prevention of neural tube defects. The supplement form has the trial evidence; food folate alone does not reliably hit the dose. For pregnancy-trying women with no MTHFR variant, 400-800 mcg of folic acid in a prenatal works. For pregnancy-trying women with documented MTHFR 677TT or with elevated homocysteine, the L-methylfolate or folinic acid form at the equivalent dose is the appropriate substitution. Coordinate with the obstetric care team.

Lactation: 500 mcg DFE per day.

Therapeutic doses for elevated homocysteine: 1-5 mg per day of L-methylfolate or folic acid, often in combination with B12 and B6. Medical management context; coordinate with the prescribing physician. The L-methylfolate form is preferable in MTHFR-variant individuals.

The 1 mg per day upper supplemental limit for synthetic folic acid. The Institute of Medicine UL is 1,000 mcg of synthetic folic acid per day from supplements and fortified food combined. Higher doses can mask the hematologic signs of B12 deficiency. The UL applies to synthetic folic acid; the L-methylfolate form is not subject to the same masking issue at higher doses because it does not bypass the megaloblastic-anemia mechanism in the same way.

Compare against typical retail labels. A standard multivitamin lists "folic acid 400 mcg DFE" (about 240 mcg actual folic acid) — covers the adult maintenance dose for most populations. A prenatal lists "folic acid 800 mcg DFE" — covers the pregnancy supplement dose. A "methylated multivitamin" or "MTHFR-conscious prenatal" lists "L-methylfolate 400 or 800 mcg DFE" — covers the same dose with the form choice that bypasses the conversion bottleneck for MTHFR-variant users.

The 1 mg masking issue

The single highest-stakes folate-label issue is the synthetic folic acid masking of B12 deficiency at doses above roughly 1 mg per day. The mechanism: B12 deficiency produces megaloblastic anemia through a folate-trapping effect that high-dose folic acid can correct independently, while the neurologic damage from B12 deficiency (subacute combined degeneration of the spinal cord, peripheral neuropathy, cognitive impairment) progresses unmasked. The hematologic signs that would have flagged the B12 deficiency are now absent, and the diagnosis is delayed until the neurologic damage is symptomatic and partially irreversible.

The risk applies to synthetic folic acid above the 1 mg/day UL, primarily in elderly populations where B12 absorption is more frequently impaired (atrophic gastritis, chronic PPI use, metformin therapy). It is less of an issue with L-methylfolate at equivalent doses and with food folate intake at any reasonable level. The buyer who self-prescribes 2-5 mg of folic acid per day on the basis of "more is better" or "I'm pregnancy-trying and want to be safe" is in the masking-risk window without the medical workup that would have caught the B12 issue. The label that ships 5 mg folic acid as an OTC product is the label that should have flagged the masking risk and almost never does.

The label patterns that distinguish a real folate product

Form specification in the supplement-facts box. "Folate, 400 mcg DFE (as L-methylfolate)" or "Folate, 400 mcg DFE (as folic acid)" tells the buyer the form. "Folate complex 400 mcg DFE" without form specification does not, and "folate complex" without disclosure is almost always folic acid because L-methylfolate is more expensive and brands that pay for it advertise the fact.

DFE-to-actual-milligrams disclosure where the form is folic acid. A label that says "folate, 680 mcg DFE (as folic acid 400 mcg)" lets the buyer see both numbers. A label that lists only the DFE leaves the conversion implicit. The buyer who needs to know the actual milligram dose (because they are tracking the 1 mg UL or because they are stacking folate-containing products) has to do the conversion themselves.

Branded methylfolate ingredients disclosed by name. Quatrefolic, Metafolin, and Magnafolate are the three main branded L-methylfolate ingredients in retail supplements. A label that names the branded ingredient ("L-methylfolate as Quatrefolic 400 mcg DFE") is signaling form fidelity and stability. A generic "L-methylfolate" or "methylfolate" claim with no brand disclosure is harder to evaluate — generic methylfolate can be the racemic mix (half-inactive D-isomer) or can have stability issues that the branded forms have addressed.

No combined folic-acid-plus-methylfolate posture without form-split disclosure. Some products list "folate as a blend of folic acid and L-methylfolate" without disclosing the split. The blend posture is usually a cost-control move — using a small fraction of methylfolate to justify the labeling claim while the bulk of the folate is the cheaper folic acid. A buyer who wants the methylfolate form should look for a single-form L-methylfolate product, not a blend.

Single-ingredient or near-single-ingredient products for the buyer who wants form control. A pure 400 or 800 mcg L-methylfolate capsule with no other actives is the test for form fidelity. Once the product is a multivitamin or a "methylation support blend" with 10-20 additional ingredients, the proprietary-blend pattern takes over and the per-ingredient dose disclosure thins.

The B12 form pairing. Folate and B12 work in the same one-carbon-metabolism pathway. A product that lists "L-methylfolate" paired with "methylcobalamin" or "hydroxocobalamin" (the more bioavailable B12 forms) is at least internally consistent on the methylation thread. A product that lists "L-methylfolate" with "cyanocobalamin" (synthetic B12 that requires conversion to the active form) is hedged — the form choice on the folate line is undone on the B12 line.

No "5-MTHF as DFE per gummy" tricks. Gummies and chewables can carry folate but the per-gummy dose is often disclosed as a DFE figure that, divided across the recommended 2-4 gummy serving, becomes a 100 mcg DFE per gummy fraction the consumer easily misreads. Read the per-serving DFE and check the serving size; the 60-second label-reading protocol catches most of these.

Where the folate-form choice matters most

The form choice (L-methylfolate or folinic acid vs folic acid) matters most for these populations:

Women trying to conceive and pregnant women with documented MTHFR 677TT or 1298 compound heterozygosity. The methylfolate or folinic acid form bypasses the conversion bottleneck. Coordinate with the obstetric care team.

Adults with documented elevated homocysteine. The active form combined with B12 and B6 is the more reliable lever. Medical management context.

Adults on long-term medications that interfere with folate metabolism. Methotrexate is the canonical example (folinic acid is the standard rescue form); sulfasalazine, certain antiepileptics (phenytoin, carbamazepine, valproate), metformin chronically, and high-dose alcohol consumption all affect folate status. Methylfolate or folinic acid is generally the better fit, in coordination with the prescribing physician.

Older adults at risk of B12 deficiency. Choose folate forms below the 1 mg/day UL to preserve the megaloblastic-anemia flag for B12 workup. The L-methylfolate form at the standard supplemental dose covers the maintenance need without the masking risk that high-dose folic acid carries.

Adults with documented Crohn's, celiac, or other malabsorption diagnoses. Absorption of either form can be impaired; the L-methylfolate form has fewer conversion-dependent steps and is often the more reliable choice. Medical-management context.

Where the form choice matters less

For adults without MTHFR variants, without medication interactions, without elevated homocysteine, without pregnancy-trying status, and without B12-masking risk, folic acid at the standard 400 mcg DFE supplemental dose works as well as L-methylfolate at the equivalent dose. The cost differential typically favors folic acid. The form choice is genuinely useful for the subset for whom it matters and less load-bearing for the general adult population. The label-marketing posture that pushes methylfolate as universally required is overselling the trial base; the label-marketing posture that treats folic acid as universally adequate is underselling the form-relevant subgroups.

The bottom line

Folate is not folic acid. Methylfolate is not folate. Folinic acid is not methylfolate. The four forms have different absorption, different conversion requirements, different dose-response curves, and different relevance depending on whether the buyer carries MTHFR variants, is on folate-interfering medications, is pregnancy-trying, or is in the B12-masking-risk window. The DFE convention on the label masks the form-and-conversion math behind a single number, and the label that does not disclose the form is not letting the buyer evaluate which protocol they are on.

For most adults, a 400 mcg DFE multivitamin folate dose works regardless of form. For the subset where the form choice matters — MTHFR variants, pregnancy planning, homocysteine elevation, folate-interfering medications, B12-masking risk — the L-methylfolate (or in specific clinical contexts, folinic acid) form bypasses the conversion bottleneck the folic-acid form depends on. The label patterns that flag a real folate product are form specification in the supplement-facts box, DFE-to-milligrams disclosure for folic-acid products, branded methylfolate ingredient names, paired methylcobalamin or hydroxocobalamin B12, absence of blend-posture marketing, and a clean serving-size-to-dose ratio.

The "folate complex 400 mcg DFE" multivitamin on the shelf is almost always folic acid wearing a more flattering label. The buyer who needs the form choice should read past the front of the bottle to the supplement-facts box, and the buyer who does not need the form choice should at least know what they are buying.